Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.82 |
| ▸ | PDE4C | Q08493 | 19/20 | 0.82 |
| ▸ | PDE4A | P27815 | 13/20 | 0.82 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.82 |
| ▸ | HTR2B | P41595 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL537170 | 0.99 | PDE4B (0.81) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL26546185 | 0.93 | PDE4B (0.82) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| Propane SCHEMBL17835994 | 0.91 | PDE4B (0.79) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL9977587 | 0.91 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1195086 | 0.91 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL537489 | 0.88 | PDE4B (0.85) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL9977589 | 0.86 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL1194004 | 0.86 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL9977553 | 0.85 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B | |
| SCHEMBL9977579 | 0.85 | PDE4B (1.00) | PDE4BPDE4CPDE4APDE4DHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149716-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | CELGENE CORPORATION | 2012-06-14 | — | — | US | disclosed |
| EP-1228071-B8 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2012-02-29 | — | — | EP | disclosed |
| EP-2263669-B1 | Pharmaceutically active isoindoline derivatives | CELGENE CORP (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110318741-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | AMGEN INC. | 2011-12-29 | — | — | US | disclosed |
| WO-2011159750-A1 | BIOMARKERS FOR THE TREATMENT OF PSORIASIS | CELGENE CORPORATION (US) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011127019-A2 | METHODS FOR TREATING RESPIRATORY VIRAL INFECTION | CELGENE CORPORATION (US) | 2011-10-13 | — | — | WO | disclosed |
| EP-1228071-B1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2007-03-28 | — | — | EP | disclosed |
| US-20060148882-A1 | Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management airway inflammation | ZELDIS JEROME B | 2006-07-06 | — | — | US | disclosed |
| EP-1228071-A4 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORP (US) | 2002-12-04 | — | — | EP | disclosed |
| EP-1228071-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001034606-A1 | PHARMACEUTICALLY ACTIVE ISOINDOLINE DERIVATIVES | CELGENE CORPORATION (US) | 2001-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149716-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING PDE4 MODULATORS FOR TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4C 3/4885PDE4A 1/4885 |
| US-20060148882-A1 | Methods of using and compositions comprising PDE4 modulators for treatment, prevention and management airway inflammation | PDE4A, PDE4B, PDE12 | PDE4B 2/4885PDE4C 6/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.